The DOI matches its Crossref record.
CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients
Open accessAbstract
Originally identified as a B-cell marker, expression of the cell surface molecule CD24 has meanwhile been observed in a variety of human malignancies. It appears to function as a ligand of P-Selectin, an adhesion molecule that is present in activated platelets and endothelial cells. We aimed to determine the rate of CD24 expression in our nonsmall cell lung cancer (NSCLC) collection and to clarify its correlation with clinicopathological parameters including patients' survival. A total of 89 NSCLC were analysed immunohistochemically using a monoclonal CD24 antibody (clone 24C02) and a standard detection system (LSAB, DAKO) on NSCLC tissue microarrays (TMA). The staining was semiquantitatively scored (0, 1+, 2+, 3+) and grouped into high (2+, 3+)- and low (0, 1+)-level expression for statistical analysis. A high level of CD24 expression was observed in 45% of the cases, preferentially adenocarcinomas. Patients whose tumours had a high CD24 expression showed a significantly shorter median survival time of 23 months vs 38 months (P=0.033, log-rank test). Similarly tumour, grading, nodal status and clinical stage were significant prognostic markers in univariate survival analysis. Importantly, in the Cox regression-based multivariate analysis, CD24 expression (P=0.025) together with tumour stage (P=0.006) and grade (P=0.011) proved to be independent prognostic parameters. We hypothesise that the decreased survival of NSCLC patients with strongly CD24-positive tumours is related to an enhanced propensity of haematogenous metastasis formation, which might be P-Selectin mediated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Balic, M., Lin, H., Young, L., Hawes, D., Giuliano, A., McNamara, G., Datar, R. H., & Cote, R. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0169 · Cited by 681
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Nakamura, K., & Smyth, M. J. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0306-1 · Cited by 516
Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM
Runz, S., Keller, S., Rupp, C., Stoeck, A., Issa, Y., Koensgen, D., Mustea, A., Sehouli, J., Kristiansen, G., & Altevogt, P. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.08.064 · Cited by 399
Self-citationAssou, S., Le Carrour, T., Tondeur, S., Ström, S., Gabelle, A., Marty, S., Nadal, L., Pantesco, V., Réme, T., Hugnot, J.-P., et al. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0352 · Cited by 350
Baumann, P., Cremers, N., Kroese, F., Orend, G., Chiquet-Ehrismann, R., Uede, T., Yagita, H., & Sleeman, J. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0619 · Cited by 333
Metadata
- Authors
- Kristiansen, G., Schlüns, K., Yongwei, Y., Denkert, C., Dietel, M., & Petersen, I.
- Venue
- British Journal of Cancer
- Published
- 2003-01
- Volume
- 88
- Issue
- 2
- Pages
- 231-236
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1979580372
- Cited by
- 168
- References
- 0
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. https://app.cochat.ai/papers/10.1038/sj.bjc.6600702
- The paper
- Kristiansen, G., Schlüns, K., Yongwei, Y., Denkert, C., Dietel, M., & Petersen, I. (2003). CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6600702
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.